MADRID, 4 Mar. (EUROPA PRESS) –

Grifols shares sank more than 9% this Monday on the stock market around 9:50 a.m., after having closed last Friday with a rebound of 18.35%, in a context marked by the publication of its 2023 accounts, which have not yet been audited by KPMG.

Specifically, Grifols opened in ‘green’, leading the rise of the Ibex 35 with a rise of 1.25%, up to 9.088 euros per share at 9:00 a.m., although minutes later it turned around, with its shares losing 9 .22%, up to 8,148 euros.

The hemoderivaodos firm has assured that “it has received written confirmation from KPMG that it expects to complete its internal procedures and issue its audit opinion before March 8, 2024, ahead of the deadline of current Spanish legislation.”

“The condensed consolidated interim financial statements have been prepared in accordance with IFRS and approved by the board of directors of Grifols,” according to the company.

The blood products firm announced in its meeting with analysts that the executive president and CEO of Grifols, Thomas Glanzmann, will become non-executive president of the company from 2025.

Glanzmann explained that this change is “in line with good governance practices” and that during this year he will work hand in hand with Nacho Abia, who will assume the position of CEO of the company as of April 1.

He added that as part of the work to improve the company’s governance, they will implement “relevant improvements whenever necessary.”

“We will simplify structures and will not carry out any new transactions with related parties,” he said in reference to Scranton and the doubts raised by Gotham City Research about the relationship between both companies.

Grifols obtained a profit of 59.3 million euros in 2023, which represents a decrease of 71.5% compared to the profits of 208.3 million recorded in the previous year, while recording record income of 6,592 million, 8.7% more.

The Catalan firm, which has achieved a positive profit and reduction in leverage, has highlighted that its net profits include “non-recurring items worth 147 million euros related, mainly, to restructuring costs”, as they have explained to Europe Press company sources.